Exchange: NASDAQ·Updated 07:56 PM EDT
News
all
press releases
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Zacks
More News
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?
Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal.
Stocktwits
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
Key PointsVertex Pharmaceuticals could face competition in its most important market by far...
Nasdaq News: Markets
IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises
IONQ posts a wider-than-expected Q2 loss but tops revenue estimates, raises its 2026 revenue outlook and sees shares rise after the results.
Zacks
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday
Key PointsIts sales rose at a double-digit rate; net profit growth was more modest...
Nasdaq News: Markets
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.
Zacks
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
Zacks
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook
Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.
Zacks
CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2
CEO Samarth Kulkarni said the second quarter showed strong progress and that the company enters the second half “well positioned, with a number of important milestones ahead across our pipeline.”
Stocktwits
Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks

Advertisement|Remove ads.